Copyright Reports & Markets. All rights reserved.

Global Axial Spondyloarthritis Drugs Market Insights, Forecast to 2025

Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Axial Spondyloarthritis Drugs Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Axial Spondyloarthritis Drugs Market Size Growth Rate by Product
      • 1.4.2 Certolizumab Pegol
      • 1.4.3 Etanercept Biosimilar
      • 1.4.4 Ixekizumab
      • 1.4.5 Secukinumab
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Axial Spondyloarthritis Drugs Market Size Growth Rate by End User
      • 1.5.2 Clinic
      • 1.5.3 Hospital
      • 1.5.4 Home Care
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Axial Spondyloarthritis Drugs Market Size
      • 2.1.1 Global Axial Spondyloarthritis Drugs Revenue 2014-2025
      • 2.1.2 Global Axial Spondyloarthritis Drugs Sales 2014-2025
    • 2.2 Axial Spondyloarthritis Drugs Growth Rate by Regions
      • 2.2.1 Global Axial Spondyloarthritis Drugs Sales by Regions
      • 2.2.2 Global Axial Spondyloarthritis Drugs Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Axial Spondyloarthritis Drugs Sales by Manufacturers
      • 3.1.1 Axial Spondyloarthritis Drugs Sales by Manufacturers
      • 3.1.2 Axial Spondyloarthritis Drugs Sales Market Share by Manufacturers
      • 3.1.3 Global Axial Spondyloarthritis Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Axial Spondyloarthritis Drugs Revenue by Manufacturers
      • 3.2.1 Axial Spondyloarthritis Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Axial Spondyloarthritis Drugs Revenue Share by Manufacturers (2014-2019)
    • 3.3 Axial Spondyloarthritis Drugs Price by Manufacturers
    • 3.4 Axial Spondyloarthritis Drugs Manufacturing Base Distribution, Product Types
      • 3.4.1 Axial Spondyloarthritis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Axial Spondyloarthritis Drugs Product Type
      • 3.4.3 Date of International Manufacturers Enter into Axial Spondyloarthritis Drugs Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Axial Spondyloarthritis Drugs Sales by Product
    • 4.2 Global Axial Spondyloarthritis Drugs Revenue by Product
    • 4.3 Axial Spondyloarthritis Drugs Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Axial Spondyloarthritis Drugs Breakdown Data by End User

    6 North America

    • 6.1 North America Axial Spondyloarthritis Drugs by Countries
      • 6.1.1 North America Axial Spondyloarthritis Drugs Sales by Countries
      • 6.1.2 North America Axial Spondyloarthritis Drugs Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Axial Spondyloarthritis Drugs by Product
    • 6.3 North America Axial Spondyloarthritis Drugs by End User

    7 Europe

    • 7.1 Europe Axial Spondyloarthritis Drugs by Countries
      • 7.1.1 Europe Axial Spondyloarthritis Drugs Sales by Countries
      • 7.1.2 Europe Axial Spondyloarthritis Drugs Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Axial Spondyloarthritis Drugs by Product
    • 7.3 Europe Axial Spondyloarthritis Drugs by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Axial Spondyloarthritis Drugs by Countries
      • 8.1.1 Asia Pacific Axial Spondyloarthritis Drugs Sales by Countries
      • 8.1.2 Asia Pacific Axial Spondyloarthritis Drugs Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Axial Spondyloarthritis Drugs by Product
    • 8.3 Asia Pacific Axial Spondyloarthritis Drugs by End User

    9 Central & South America

    • 9.1 Central & South America Axial Spondyloarthritis Drugs by Countries
      • 9.1.1 Central & South America Axial Spondyloarthritis Drugs Sales by Countries
      • 9.1.2 Central & South America Axial Spondyloarthritis Drugs Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Axial Spondyloarthritis Drugs by Product
    • 9.3 Central & South America Axial Spondyloarthritis Drugs by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Axial Spondyloarthritis Drugs by Countries
      • 10.1.1 Middle East and Africa Axial Spondyloarthritis Drugs Sales by Countries
      • 10.1.2 Middle East and Africa Axial Spondyloarthritis Drugs Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Axial Spondyloarthritis Drugs by Product
    • 10.3 Middle East and Africa Axial Spondyloarthritis Drugs by End User

    11 Company Profiles

    • 11.1 AstraZeneca Plc
      • 11.1.1 AstraZeneca Plc Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 AstraZeneca Plc Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 AstraZeneca Plc Axial Spondyloarthritis Drugs Products Offered
      • 11.1.5 AstraZeneca Plc Recent Development
    • 11.2 Eli Lilly and Company
      • 11.2.1 Eli Lilly and Company Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Eli Lilly and Company Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Eli Lilly and Company Axial Spondyloarthritis Drugs Products Offered
      • 11.2.5 Eli Lilly and Company Recent Development
    • 11.3 Johnson & Johnson
      • 11.3.1 Johnson & Johnson Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Johnson & Johnson Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Johnson & Johnson Axial Spondyloarthritis Drugs Products Offered
      • 11.3.5 Johnson & Johnson Recent Development
    • 11.4 Novartis AG
      • 11.4.1 Novartis AG Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Novartis AG Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Novartis AG Axial Spondyloarthritis Drugs Products Offered
      • 11.4.5 Novartis AG Recent Development
    • 11.5 Panacea Biotec Ltd
      • 11.5.1 Panacea Biotec Ltd Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Panacea Biotec Ltd Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Panacea Biotec Ltd Axial Spondyloarthritis Drugs Products Offered
      • 11.5.5 Panacea Biotec Ltd Recent Development
    • 11.6 Sandoz International GmbH
      • 11.6.1 Sandoz International GmbH Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Sandoz International GmbH Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Sandoz International GmbH Axial Spondyloarthritis Drugs Products Offered
      • 11.6.5 Sandoz International GmbH Recent Development
    • 11.7 Sun Pharma Advanced Research Company Ltd
      • 11.7.1 Sun Pharma Advanced Research Company Ltd Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Products Offered
      • 11.7.5 Sun Pharma Advanced Research Company Ltd Recent Development
    • 11.8 UCB SA
      • 11.8.1 UCB SA Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 UCB SA Axial Spondyloarthritis Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 UCB SA Axial Spondyloarthritis Drugs Products Offered
      • 11.8.5 UCB SA Recent Development

    12 Future Forecast

    • 12.1 Axial Spondyloarthritis Drugs Market Forecast by Regions
      • 12.1.1 Global Axial Spondyloarthritis Drugs Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Axial Spondyloarthritis Drugs Revenue Forecast by Regions 2019-2025
    • 12.2 Axial Spondyloarthritis Drugs Market Forecast by Product
      • 12.2.1 Global Axial Spondyloarthritis Drugs Sales Forecast by Product 2019-2025
      • 12.2.2 Global Axial Spondyloarthritis Drugs Revenue Forecast by Product 2019-2025
    • 12.3 Axial Spondyloarthritis Drugs Market Forecast by End User
    • 12.4 North America Axial Spondyloarthritis Drugs Forecast
    • 12.5 Europe Axial Spondyloarthritis Drugs Forecast
    • 12.6 Asia Pacific Axial Spondyloarthritis Drugs Forecast
    • 12.7 Central & South America Axial Spondyloarthritis Drugs Forecast
    • 12.8 Middle East and Africa Axial Spondyloarthritis Drugs Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Axial Spondyloarthritis Drugs Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Axial Spondyloarthritis Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Axial Spondyloarthritis Drugs market based on company, product type, end user and key regions.

      This report studies the global market size of Axial Spondyloarthritis Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Axial Spondyloarthritis Drugs in these regions.
      This research report categorizes the global Axial Spondyloarthritis Drugs market by top players/brands, region, type and end user. This report also studies the global Axial Spondyloarthritis Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      AstraZeneca Plc
      Eli Lilly and Company
      Johnson & Johnson
      Novartis AG
      Panacea Biotec Ltd
      Sandoz International GmbH
      Sun Pharma Advanced Research Company Ltd
      UCB SA

      Market size by Product
      Certolizumab Pegol
      Etanercept Biosimilar
      Ixekizumab
      Secukinumab
      Others
      Market size by End User
      Clinic
      Hospital
      Home Care

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Axial Spondyloarthritis Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Axial Spondyloarthritis Drugs market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Axial Spondyloarthritis Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Axial Spondyloarthritis Drugs submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Axial Spondyloarthritis Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Axial Spondyloarthritis Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now